Primary Membranous Nephropathy

Nephrology
6
Pipeline Programs
5
Companies
4
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
3
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

BeOne Medicines
BRUKINSAApproved
zanubrutinib
BeOne Medicines
Kinase Inhibitor [EPC]oral2025

Competitive Landscape

5 companies ranked by most advanced pipeline stage

BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
1
ZanubrutinibPhase 2/3Small Molecule1 trial
Active Trials
NCT05707377Active Not Recruiting178Est. Oct 2027
Biogen
BiogenCAMBRIDGE, MA
1 program
1
FelzartamabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06962800Recruiting180Est. Mar 2029
Zai Lab
Zai LabCA - South SF
1 program
1
PovetaciceptPhase 2/31 trial
Active Trials
NCT07204275Recruiting176Est. Dec 2028
VP
1 program
1
PovetaciceptPhase 2/3
Climb Bio
Climb BioMA - Wellesley Hills
1 program
1
budoprutugPhase 21 trial
Active Trials
NCT07096843RecruitingEst. Oct 2027

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
BiogenFelzartamab
Zai LabPovetacicept
BeOne MedicinesZanubrutinib
Climb Biobudoprutug

Clinical Trials (4)

Total enrollment: 534 patients across 4 trials

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Start: May 2025Est. completion: Mar 2029180 patients
Phase 3Recruiting
NCT07204275Zai LabPovetacicept

A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Start: Sep 2025Est. completion: Dec 2028176 patients
Phase 2/3Recruiting

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Start: Apr 2023Est. completion: Oct 2027178 patients
Phase 2/3Active Not Recruiting

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Start: Aug 2025Est. completion: Oct 2027
Phase 2Recruiting

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 534 patients
5 companies competing in this space